Study findings on ovarian cancer are outlined in reports from University of Texas
2009 AUG 3 - (NewsRx.com) -- In this recent article published in the International Journal of Gynecological Cancer, scientists in the United States conducted a study "To assess the association between patient-disease characteristics and overall Survival (OS) after second-fine intraperitoneal (IP) treatment of ovarian cancer. Data were aggregated from 7 Gynecologic Oncology Group (GOG) phase 2 Studies conducted between 1988 and 1995 10 evaluate IP therapy for partially responsive or recurrent disease but no turner masses greater than 0.5 cm." "Factors evaluated include age, performance status, extent of residual disease, turner grade, and histologic diagnosis. A total of 432 eligible women were treated on I of the 7 second-line phase 2 IP trials. The median OS was 2.4 years (range of individual study medians, 1.9-2.9 years). Relative to women with grade I cancers, those with grade 2 or 3 cancers experienced 1.82 (95% confidence interval [Cl], 1.21-2.74) and 2.02 (95% Cl, 1.35-3.03) times greater instantaneous death rates, respectively, and those with clear cell adenocarcinoma experienced death rates 6.00 (95% Cl, 3.27-10.9) times greater. The extent of residual disease, surgically assessed before starting Study treatment, was also associated with OS. Relative to those who had no evidence of gross disease, those with gross disease that was completely resected, or With unresectable disease (not larger than 0.5 cm), experienced death rates 1.74 (95% Cl, 1.25-2.42) and 2.26 (95% Cl, 1.67-3.05) times greater, respectively. There are patient and disease characteristics strongly associated with survival after second-line IP treatments," wrote M. Markman and colleagues, University of Texas. The researchers concluded: "These factors are relevant to clinicians considering IP therapy outside the investigative setting and for the development of future studies in this area.." Markman and colleagues published their study in International Journal of Gynecological Cancer (Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience. International Journal of Gynecological Cancer, 2009;19(2):223-229). Additional information can be obtained by contacting M. Markman, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Mail Box 121, Houston, TX 77030, USA. The publisher of the International Journal of Gynecological Cancer can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA. Keywords: United States, Houston, Chemotherapy, Cisplatin, Clinical Trial Research, Drug Therapy, Drugs, Gynecology, Oncology, Ovarian Cancer, Ovarian Carcinoma, Paclitaxel, Pharmaceuticals, Treatment, Women's Health, University of Texas. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
